Citation

Lousberg L, Jerusalem G. Breast Cancer: Basic and Clinical Research 2016; 10: 239-252.

Copyright

(Copyright © 2016)

DOI

10.4137/BCBCR.S12443

PMID

unavailable

Abstract

Everolimus combined with exemestane is an important treatment option for patients suffering from estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer (ABC) who have been previously treated with a nonsteroidal aromatase inhibitor (NSAI). After presentation of phase III registration trial BOLERO-2, several phase IIIb trials have been started to evaluate this regimen in a more real-world setting. Here, we review the efficacy and safety data published or presented at selected international meetings. These studies confirmed the outcome observed in the BOLERO-2 trial. Patient acceptance rate is also discussed by focusing on the permanent everolimus discontinuation rate in these trials. Factors influencing the safety profile are also reported, including the impact of age. The optimal sequence of combined therapy approaches associating targeted and endocrine therapy (ET) has yet to be determined as new treatment options such as cyclin-dependent kinase inhibitors become available. However, everolimus-exemestane remains an important treatment option with a major impact on progression-free survival (PFS) and an acceptable safety profile. © the authors, publisher and licensee Libertas Academica Limited.

Language: en

Keywords

Safety; human; suicide; quality of life; Treatment; liver failure; cause of death; treatment outcome; disease severity; kidney failure; fatigue; retrospective study; weight reduction; tamoxifen; thrombocytopenia; lung embolism; drug safety; drug blood level; cerebrovascular accident; sepsis; drug efficacy; diarrhea; drug tolerability; nausea; Efficacy; fever; hypercholesterolemia; rash; lung edema; side effect; diabetes mellitus; enzyme inhibition; asthenia; hyperlipidemia; anemia; drug half life; creatinine; creatinine blood level; respiratory failure; drug elimination; deterioration; dyspnea; coughing; paclitaxel; pneumonia; Breast cancer; hyperglycemia; adult respiratory distress syndrome; cancer recurrence; body mass; treatment response; Article; open study; progression free survival; overall survival; cancer growth; stomatitis; cancer chemotherapy; febrile neutropenia; decreased appetite; trastuzumab; randomized controlled trial (topic); cardiopulmonary insufficiency; exemestane; letrozole; capecitabine; angiogenesis; meta analysis (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); everolimus; Everolimus; mammalian target of rapamycin complex 1; metastatic breast cancer; noninfectious pneumonitis; phase 4 clinical trial (topic); Progression-free survival; staphylococcal bacteremia; tumor bleeding